InvestorsHub Logo
Followers 1751
Posts 27356
Boards Moderated 3
Alias Born 04/04/2017

Re: None

Thursday, 11/21/2024 2:52:30 PM

Thursday, November 21, 2024 2:52:30 PM

Post# of 36829
Cardiff Lexington Announces Third Quarter 2024 Financial Results

LEXINGTON, KY / ACCESSWIRE / November 21, 2024 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its third quarter and nine months ended September 30, 2024.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "Operationally, our business performed well during the quarter. We opened our 12th Nova Ortho and Spine location in Orlando, Florida, establishing Nova Ortho and Spine in a major metropolitan area with greater population density and higher traffic, and saw an increase in booked procedures which generally bodes well for future revenues. That said, the severe weather across Florida during the quarter has delayed many procedures. Also, our GAAP revenue was negatively impacted in the quarter due to a change in estimate related to our claim settlement realization rate that better aligns third quarter revenue with 2024 annualized rates. Adjusted revenue for the quarter, excluding this one-time change in estimate, was $3.0 million. It is our expectation that revenue will return to more historical levels going forward and grow as we strengthen our working capital to support the long-term growth of our business."

"Demand is strong, and we continue to identify strategic locations to establish new Nova Ortho and Spine offices and expand our network of healthcare services. Our shareholders' equity has grown 410% since the beginning of the year, and with our visibility today, we believe that we are on track to deliver enhanced long-term performance supported by a robust network of locations and a strong reputation as a high-quality medical care provider," Mr. Cunningham concluded.

Third Quarter 2024 Financial Results

Total revenue was $1,355,641. Revenue in the third quarter included a one-time non-cash adjustment of $1,650,474 to better align third quarter revenue with 2024 annualized claim settlement realization rates. Non-GAAP adjusted revenue, excluding the one-time non-cash adjustment, was $3,006,115
Cost of sales in the quarter increased to $1,000,601 primarily related to laboratory fees
Selling, general, and administrative expenses of $936,835 primarily related to increased salaries and wages as the Company continues to invest in its growth
Loss from continuing operations was $585,160
Non-GAAP adjusted EBITDA was $1,061,912

Nine Months 2024 Financial Results

Total revenue was $5,149,416. Revenue for the nine months ended September 30, 2024, included a one-time non-cash adjustment of $1,650,474 to better align third quarter 2024 revenue with 2024 annualized claim settlement realization rates. Non-GAAP adjusted revenue, excluding this one-time non-cash adjustment, was $6,799,890
Cost of sales for the nine-month period was $2,741,765
Selling, general, and administrative expenses of $2,622,981 primarily related to increased salaries and wages as the Company continues to invest in its growth
Loss from continuing operations was $525,651. Included in operating expenses for the nine months ended September 30, 2024 were Non-GAAP increased expenses associated with the anticipated growth of the business of $596,225
Non-GAAP Adjusted EBITDA was $1,507,928

Balance Sheet Highlights (September 30, 2024, compared to December 31, 2023)

125% increase in cash to $1,949,600
13% increase in total assets to $23,514,762
410% increase in shareholders' equity to $3,729,120

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(UNAUDITED)





Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30,






September 30,






September 30,






September 30,






2024






2023 (Restated)






2024






2023 (Restated)


Total revenue




$


1,355,641






$


3,405,859






$


5,149,416






$


9,476,764


Total cost of sales






1,000,601








551,423








2,741,765








2,589,407


Gross profit






355,040








2,854,436








2,407,651








6,887,357


Operating expenses
































Depreciation expense






3,365








3,365








10,096








11,365


Selling, general and administrative






936,835








577,677








2,622,981








2,095,611


Stock compensation expense






0








0








300,225








0


Total operating expenses






940,200








581,042








2,933,302








2,106,976


(Loss) income from continuing operations






(585,160


)






2,273,394








(525,651


)






4,780,381


































Other income (expense):
































Other (expense) income






(6,767


)






(1


)






(4,720


)






204


Gain on debt refinance, forgiveness and settlement






0








0








78,834








390


Penalties and fees






0








(16,000


)






(1,330


)






(48,000


)
Interest expense






(1,386,041


)






(226,119


)






(1,803,657


)






(1,763,698


)
Amortization of debt discounts






0








(46,048


)






(24,821


)






(94,664


)
Total other (expense) income






(1,392,808


)






(288,168


)






(1,755,694


)






(1,905,768


)
Net (loss) income before discontinued operations






(1,977,968


)






1,985,226








(2,281,345


)






2,874,613


Loss from discontinued operations






0








(3,705


)






(111,312


)






(93,005


)

































Net (loss) income




$


(1,977,968


)




$


1,981,521






$


(2,392,657


)




$


2,781,608


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023
(UNAUDITED)





September 30,






December 31,






2024






2023 (Restated)


ASSETS












Current assets












Cash




$


1,949,600






$


866,943


Accounts receivable-net






14,798,220








13,305,254


Prepaid and other current assets






5,000








5,000


Total current assets






16,752,820








14,177,197


















Property and equipment, net






24,563








34,661


Land






540,000








540,000


Goodwill






5,666,608








5,666,608


Right of use - assets, net






465,389








289,062


Due from related party






4,979








4,979


Other assets






60,403








33,304


Total assets




$


23,514,762






$


20,745,811


















LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY
















Current liabilities
















Accounts payable and accrued expense




$


1,386,412






$


2,047,131


Accrued expenses - related parties






4,353,056








4,733,057


Accrued interest






361,172








620,963


Right of use - lease liabilities






227,606








157,669


Due to director and officer






0








120,997


Notes payable - current portion






500,826








15,977


Line of credit






7,468,971








2,120,100


Convertible notes payable, net of debt discounts of $0 and $24,820, respectively






105,000








3,807,030


Net liabilities of discontinued operations






237,643








237,643


Total current liabilities






14,640,686








13,860,567


















Other liabilities
















Notes payable






140,272








144,666


Operating lease liability - long term






236,853








119,056


Total liabilities






15,017,811








14,124,289


















Mezzanine equity
















Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 868,056 shares issued and outstanding at September 30, 2024 and December 31, 2023






3,230,023








3,891,439


Redeemable Series R Senior Convertible Preferred Stock - 5,000 shares authorized, $0.001 par value, stated value of $1,200, 0 and 165 shares issued and outstanding at September 30, 2024 and December 31, 2023






0








307,980


Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 375,000 shares issued and outstanding at September 30, 2024 and December 31, 2023






1,537,808








1,690,685


Total Mezzanine Equity






4,767,831








5,890,104


















Stockholders' equity
















Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 753,929 and 2,139,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






3,015,716








8,557,912


Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 43 and 123 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






172








492


Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 75,375 and 155,750 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






301,500








623,000


Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 9,500 and 35,752 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






38,000








143,008


Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 11,540,500 and 14,885,000 issued and outstanding at September 30, 2024 and December 31, 2023, respectively






46,162,200








59,540,000


Series J Preferred Stock - 2,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 1,713,584 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






-








6,854,336


Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at September 30, 2024 and December 31, 2023






1,277,972








1,277,972


Series Y Senior Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value of $4.00, 955,114 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively






3,820,456








-


Common Stock - 300,000,000 shares authorized, $0.001 par value; 14,555,601 and 25,121 shares issued and outstanding at September 30, 2024 and December 31, 2023






14,556








25


Additional paid-in capital






20,891,337








(7,581,212


)
Accumulated deficit






(71,792,589


)






(68,684,115


)
Total stockholders' equity






3,729,120








731,418


Total liabilities, mezzanine equity and stockholders' equity




$


23,514,762






$


20,745,811


CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023
(UNAUDITED)

The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)




Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30,






September 30,






2024






2023 (Restated)






2024






2023 (Restated)


EBITDA (1)
























Net (loss) income before discontinued operations




$


(1,977,968


)




$


1,985,226






$


(2,281,345


)




$


2,874,613


Add:
































Interest






1,386,041








226,119








1,803,657








1,763,698


Taxes






0








0








0








0


Depreciation






3,365








3,365








10,096








11,365


Amortization






0








46,048








24,821








94,664


































EBITDA (1)




$


(588,562


)




$


2,260,758






$


(442,771


)




$


4,744,340


































Adjusted EBITDA (2)
































EBITDA




$


(588,562


)




$


2,260,758






$


(442,771


)




$


4,744,340


Add:
































Change in estimate for settlement realization rate






1,650,474








0








1,650,474








0


Stock compensation expense for shares issued






0








0








300,225








0


































































Adjusted EBITDA (2)




$


1,061,912






$


2,260,758






$


1,507,928






$


4,744,340


































(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.






























(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.






























CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF REVENUE FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
(UNAUDITED)





Unaudited






Unaudited






For the Three Months Ended






For the Nine Months Ended






September 30, 2024






September 30, 2024














GAAP Revenue




$


1,355,641






$


5,149,416


Adjustment to Claim Settlement Realization Rate






1,650,474








1,650,474


Non-GAAP Adjusted Revenue






3,006,115








6,799,890


Contact Information

Walter Frank
Investor Relations
cardifflexington@imsinvestorrelations.com
2039729200

SOURCE: Cardiff Lexington Corporation


View the original press release on accesswire.com

© Copyright 2024 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CDIX/news/story?e&id=3054537
Bullish
Bullish

Buy and sell at your own risk, I am not a financial advisor, all my posts are for entertainment only, enter at your own risk!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDIX News